pioglitazone has been researched along with Mitochondrial Diseases in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Mitochondrial Diseases: Diseases caused by abnormal function of the MITOCHONDRIA. They may be caused by mutations, acquired or inherited, in mitochondrial DNA or in nuclear genes that code for mitochondrial components. They may also be the result of acquired mitochondria dysfunction due to adverse effects of drugs, infections, or other environmental causes.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Differentiated SH-SY5Y neuroblastoma cells were exposed to the PD relevant mitochondrial complex 1 inhibitor 1-methyl-4-phenylpyridinium iodide (MPP+)." | 3.83 | Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis. ( Carroll, CB; Eastwood, J; Hanemann, CO; McCorry, K; Zajicek, JP; Zeissler, ML, 2016) |
| "Pioglitazone treatment restored in vivo muscle oxidative capacity in diabetic rats to the level of lean controls." | 1.42 | Pioglitazone treatment restores in vivo muscle oxidative capacity in a rat model of diabetes. ( Ciapaite, J; Houten, SM; Nicolay, K; Prompers, JJ; van den Broek, NM; Wessels, B, 2015) |
| "Treatment with Pioglitazone prevented the increase in the number of activated microglia and no difference was observed between sham and Pioglitazone-treated animals." | 1.37 | Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. ( Bing, G; Gao, J; Liu, M; Pauly, JR; Readnower, R; Sauerbeck, A; Sullivan, PG, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wassef, MAE | 1 |
| Tork, OM | 1 |
| Rashed, LA | 1 |
| Ibrahim, W | 1 |
| Morsi, H | 1 |
| Rabie, DMM | 1 |
| Wessels, B | 1 |
| Ciapaite, J | 1 |
| van den Broek, NM | 1 |
| Houten, SM | 1 |
| Nicolay, K | 1 |
| Prompers, JJ | 1 |
| Zeissler, ML | 1 |
| Eastwood, J | 1 |
| McCorry, K | 1 |
| Hanemann, CO | 1 |
| Zajicek, JP | 1 |
| Carroll, CB | 1 |
| Sauerbeck, A | 1 |
| Gao, J | 1 |
| Readnower, R | 1 |
| Liu, M | 1 |
| Pauly, JR | 1 |
| Bing, G | 1 |
| Sullivan, PG | 1 |
4 other studies available for pioglitazone and Mitochondrial Diseases
| Article | Year |
|---|---|
Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.
Topics: Animals; Cardiolipins; Diabetic Cardiomyopathies; Disease Models, Animal; Exenatide; Hypoglycemic Ag | 2018 |
Pioglitazone treatment restores in vivo muscle oxidative capacity in a rat model of diabetes.
Topics: Animals; Biomarkers; Carnitine; Diabetes Mellitus, Type 2; Hypertriglyceridemia; Hypoglycemic Agents | 2015 |
Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis.
Topics: 1-Methyl-4-phenylpyridinium; Cell Line, Tumor; Dronabinol; Humans; Mitochondria; Mitochondrial Disea | 2016 |
Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury.
Topics: Analysis of Variance; Animals; Brain Injuries; CD11b Antigen; Cerebral Cortex; Cognition Disorders; | 2011 |